FindTrial
Sign In

Clinical test of safety and effectiveness of Stem cell Screen–Enrich–Combine(-Biomaterials) Circulating System (SECCS)

Stem cell Screen–Enrich–Combine(-Biomaterials) Circulating System(SECCS): An innovation for promoting bone regeneration

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17011448
Enrollment
Unknown
Registered
2017-05-20
Start date
2013-06-09
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone defect

Interventions

intervention group:MSC/TCP graft

Sponsors

Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. aged between 15-65 years old, gender is not limited; 2. patients were diagnosed as bone defect, requiring bone regeneration; 3. patient who sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. malignant tumor; 2. myelodysplastic syndromes; 3. infection; 4. post high-dose radiotherapy and chemotherapy; 5, hematopoietic diseases.

Design outcomes

Primary

MeasureTime frame
Stem cell enrichment effeciency;bone regeneration;—

Secondary

MeasureTime frame
cell viability;Bacteriological examination;—

Countries

China

Contacts

Public ContactKerong Dai

Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

krdai@163.com13946514762

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026